Poster Presentation Clinical Oncology Society of Australia Annual Scientific Meeting 2026

Improving clinical trial access, awareness and collaboration across NSW: Findings from a statewide program evaluation (146482)

Maria Mury 1 , Lindsey Jasicki 1 , Melissa Minett 1 , Brooke Stapleton 1 , Barbara Daveson 1
  1. Cancer Institute NSW, St Leonards, NSW, Australia

Introduction 

Clinical trials are a foundation of high-quality cancer research. Improving awareness, access and participation in clinical trials is a priority of the NSW Cancer Plan.

The Cancer Institute NSW monitors clinical trial participation across NSW and delivers statewide initiatives to improve clinical trial availability, awareness, access and collaboration.

Aim

To describe findings from an evaluation of statewide initiatives delivered between 2022 and 2024 that support clinical trial participation, awareness, access and collaboration across NSW.

Methods

Underpinned by a program logic model, a mixed-methods evaluation was conducted to assess the implementation and early effectiveness of statewide initiatives designed to improve clinical trial availability, participation, awareness, access and collaboration.

Results

  • The number of cancer clinical trials open for recruitment increased from 766 to 795.
  • Over 6,400 enrolments were recorded, and approximately 5.3% of people diagnosed with cancer in NSW participated in a clinical trial.
  • Participation varied across population groups. Participation among culturally and linguistically diverse (CALD) populations was 3.1%, compared with the NSW average of 5.3%.
  • To support awareness and access among priority populations, three clinical trial information resources were translated into 20 languages, which were accessed 326 times. Three local health districts (LHDs) reported incorporating these resources into clinical practice.
  • Primary care resources received 704 webpage visits.
  • Ten workforce education sessions, supporting workforce capability and collaboration, reached 289 participants from 13 LHDs.

Conclusion

This evaluation highlights the Cancer Institute NSW's statewide approach to monitoring participation, identifying access gaps and implementing initiatives. Findings demonstrate the reach and uptake of consumer information, primary care engagement and workforce education activities designed to support clinical trial recruitment and participation across NSW. Together, these initiatives contribute to building capability and collaboration across the cancer system, helping more patients consider opportunities to participate in cancer research and supporting a more equitable and sustainable clinical trials system.